Tin t&#x1EE9;c &amp; C&#x1EAD;p nh&#x1EAD;t

The incidence of depression among older adults with type 2 diabetes is low, and the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) helps reduce the risk of depression relative to dipeptidyl peptidase-4 inhibitors (DPP4is), but not sodium–glucose cotransporter-2 inhibitors (SGLT2is).

GLP-1RAs lower depression risk in older adults with T2D

Five BP readings establish BP variability to predict cardiac risk in diabetics

Long-term visit-to-visit variability in blood pressure (BP) may be used to predict cardiovascular outcomes in people with diabetes, suggests a study. At least five BP measurements are necessary to effectively estimate intraindividual VVV and assess cardiovascular risk.

Five BP readings establish BP variability to predict cardiac risk in diabetics

Real-world study: Combining SGLT2i and pioglitazone may ameliorate at-risk MASH in T2D patients

03 Mar 2025 bởi

Combined use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and pioglitazone may be a potentially useful strategy to ameliorate metabolic dysfunction–associated steatohepatitis (MASH) in patients with type 2 diabetes (T2D), according to a real-world study conducted by researchers from the University of Hong Kong and Queen Mary Hospital (QMH).

Real-world study: Combining SGLT2i and pioglitazone may ameliorate at-risk MASH in T2D patients

03 Mar 2025

Weight loss plays crucial role in diabetes remission

02 Mar 2025

Bodyweight loss appears to have a strong, independent dose-response association with type 2 diabetes (T2D) remission among people with obesity or overweight, according to the results of a meta-analysis.

Weight loss plays crucial role in diabetes remission

02 Mar 2025

Comorbid hypertension, diabetes up CVD, death risks

The dual presence of hypertension and diabetes in an individual puts them at increased risks of cardiovascular disease (CVD) and all-cause mortality beyond those associated with either condition alone, reveals a study.

Comorbid hypertension, diabetes up CVD, death risks

Sotagliflozin: First SGLT inhibitor to show ischaemic benefit

The dual sodium–glucose co-transporter (SGLT) 1/2 inhibitor sotagliflozin appears to reduce the risk of major adverse cardiovascular events (MACE), especially myocardial infarction and stroke—a benefit that has not been previously observed with other drugs of the same class—in patients with type 2 diabetes, chronic kidney disease, and additional cardiovascular risk, according to the secondary analysis of the SCORED trial.

Sotagliflozin: First SGLT inhibitor to show ischaemic benefit

Do GLP-1 RAs reduce VTE risk in T2D?

28 Feb 2025 bởi

New data from a study of 656,588 patients with type 2 diabetes (T2D) demonstrate a lower risk of venous thromboembolism (VTE), regardless of obesity status, when treated with glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1 RAs).

Do GLP-1 RAs reduce VTE risk in T2D?

28 Feb 2025

Semaglutide linked to modest increase in risk of nonarteritic anterior ischemic optic neuropathy

The use of semaglutide among individuals with type 2 diabetes (T2D) appears to carry a modest increase in the risk nonarteritic anterior ischemic optic neuropathy (NAION), according to a retrospective study.

Semaglutide linked to modest increase in risk of nonarteritic anterior ischemic optic neuropathy

Obesity impacts symptom severity, prednisone dosing in PMR

Obesity appears to have an impact on both symptom severity and the use of prednisone in patients with polymyalgia rheumatica (PMR), suggests a study. This is potentially driven by subjective pain perception rather than increased inflammation.

Obesity impacts symptom severity, prednisone dosing in PMR